

LABORATOIRE DE THERAPIE CELLULAIRE CLINIQUE

LISTE DES PUBLICATIONS

1. Effect of alpha and gamma interferon on CFU-GM. Delforge A., Stryckmans P., Lagneaux L., Vandenplas B., Loos M., Bron D. **Blood** 67 : 251, 1986. (FI: 9.745)
2. Elevation of IgE-binding factors in serum of patients with B-cell derived chronic lymphoblastic leukemia. Sarfati M., Bron D., Lagneaux L., Fonteyn C., Frost H., Delespesse G. **Blood** 71(1) : 94-98, 1988. (FI: 9.745)
3. Contribution des anticorps monoclonaux au diagnostic et au pronostic des leucémies aiguës (à propos de 100 cas).Bernier M., Massy M., Delforge A., Lagneaux L., Bron D., Debusscher L., Stryckmans P. **Revue Médicale de Bruxelles** 9 : 448-454, 1988.
4. Comparison of in vitro inhibition of etoposide (VP 16) on leukemic and normal myeloid, erythroid clonogenic cells. Lagneaux L., Marie J.P., Delforge A., Socquet M., Thevenin D., Zittoun R., Stryckmans P. **Experimental Hematology** 17:843-846,1989. (FI: 3.198)
5. Production of human monoclonal IgG antibodies to cytomegalovirus (CMV). D. Bron, A. Delforge, L. Lagneaux, G. de Martinoff, Ph. Van Der Auwera, R. Snoeck, A. Burny, P. Stryckmans.**Journal of Immunological Methods** 130:209-216,1990. (FI: 2.598)
6. Recombinant interferons alpha and/or gamma and in vitro proliferation of myeloid and leukemic progenitors. A.Delforge, B. Vandenplas, L. Lagneaux, M. Loos, D. Bron, L. Debusscher, P. Stryckmans. **European Journal of Haematology** 44:307-311,1990. (FI: 1.807)
7. Inhibitory effects of potent anti-HIV and anti-CMV compounds on the growth of human granulocyte-macrophage progenitor cells in vitro. R. Snoeck, L. Lagneaux, A. Delforge, D. Bron, P. Stryckmans, J. Balzarini, E. De Clercq. **European Journal of Clinical Microbiology and Infectious Diseases** 9:615-619,1990. (FI: 1.333)
8. Prevention of CMV-induced myelosuppression by anti-CMV antibodies : an in vitro model. D. Bron, L. Lagneaux, A. Delforge, C. Otte, R. Snoeck, P. Stryckmans. **Experimental Hematology** 19:132-135,1991. (FI: 3.198)
9. Excessive production of TGF β by bone marrow stromal cells in B-cell chronic lymphocytic leukemia (B-CLL) inhibits growth of hematopoietic precursors and IL-6 production. L. Lagneaux, A. Delforge, C. Dorval, D. Bron, P. Stryckmans.**Blood** 82:2379-2385,1993. (FI: 9.745)
10. Cytomegalovirus-mediated myelosuppression. L. Lagneaux, A. Delforge, P. Stryckmans, D. Bron. **Experimental Hematology** 21:4,1993. (FI: 3.198)

11. Perturbation of cytokine production by bone marrow stromal cells after cytomegalovirus infection. L. Lagneaux, A. Delforge, R. Snoeck, E. De Clercq, P. Stryckmans, D. Bron. In : Multidisciplinary approach to understanding cytomegalovirus disease. Ed S. Michelson, **Excerpta Medica** 1993;111-116.
12. Excessive production of TGF- β by bone marrow stromal cells in B-cell chronic lymphocytic leukemia (B-CLL) inhibits growth of hematopoietic precursors and IL-6 production by the stromal cells. P. Stryckmans, L. Lagneaux, C. Dorval, D. Bron, E. Bosmans, A. Delforge. In : **The Inhibitors of Hematopoiesis**, John Libbey Ed,1993.
13. Alloactivation induced during MLR by HLA class II differences provokes release by macrophages of tumor necrosis factor- α and interleukin-6 and primes them to lipopolysaccharides. M.Toungouz., C. Denys , D. De Groote, M. Andrien, E. Dupont.**Hum Immunol**, 38, 1993: 221-225 (**FI: 2.6**)
14. Effects of two different dosages of aprotinin on perioperative blood loss during liver transplantation. B. Ickx, O. Pradier, F. Degroote, C. Hendrice, M. Toungouz, Vandestadt J., Gelin M. and P. Capel. **Seminars in thrombosis and hemostasis**, 19, 1993:300-301 (**FI: 5**).
15. HLA-B locus DNA typing: Detection of B*7801 and seven additional alleles by Bw6-specific exon 2 amplification. M. Andrien, J.-M. Tiercy , V. Defleur, C. Bouillenne, M. Toungouz, M. Jeannet and E. Dupont. **Tissue Antigens**, 42, 1993: 480-487 (**FI: 3**).
16. Decreased production of cytokines after CMV infection of marrow-derived stromal cells. L. Lagneaux, A. Delforge, R. Snoeck, P. Stryckmans, D. Bron. **Experimental Hematology** 22:26-30,1994. (**FI: 3.198**)
17. Tumor necrosis factor- α and interleukin-6 production induced by variations of DR4 polymorphism during the primary mixed lymphocyte reaction. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. **Transplantation**, 58, 1994: 1393-1398 (**FI: 3.5**).
18. Comparative analysis of cytokines released by bone marrow L. Lagneaux, A. Delforge, D. Bron, E. Bosmans, P. Stryckmans. **Leukemia & Lymphoma** 17:127-133,1995. (**FI: 1.134**)
19. HLA-DR subtypes induce IL-6 and TNF- α production in primary mixed lymphocyte reaction. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. **Transpl Proc**, 27, 1995: 461-462 (**FI: 0.6**).
20. In vitro inhibition of tumor necrosis factor- α and interleukin-6 production by intravenous immunoglobulins. M. Toungouz, C. Denys, D. De Groote, E. Dupont. **Brit J Haematol**, 89(4), 1995: 698-703 (FI: 3.2).

21. IL-12 unmasks HLA class I differences during MLR induced IFN- γ production. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. **Hum Immunol**, 44, 1995:145-155 (FI: 2.6).
22. Human cytomegalovirus increases constitutive production of interleukin-6 and leukemia inhibitory factors by bone marrow stromal cells. L. Lagneaux, A. Delforge, R. Snoeck, E. Bosmans, JF Moreau, JL Taupin, E. De Clercq, P. Stryckmans, D. Bron. **Blood** 87:59-66,1996. (FI: 9.745)
23. Imbalance in production of cytokines by bone marrow stromal cells during cytomegalovirus (CMV) infection. L. Lagneaux, A. Delforge, R. Snoeck, E. Bosmans, D. Schols, E. DeClercq, P. Stryckmans, D. Bron. **Journal of Infectious Disease** 174:913-919,1996. (FI: 5.418)
24. New insight in the pathogenesis and treatment of CMV. D. Bron, R. Snoeck, L. Lagneaux. **Expert Opinion on Investigational Drugs** 5:1-8,1996. (FI: 3.044))
25. Optimal control of IFN- γ and TNF- α by IL-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. **Transplantation**, 61, 1996:497-502 (FI: 3.5).
26. Regulation of IFN- γ during the mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, E. Dupont. **Transpl Proc**, 28, 1996:2911-2912 (FI: 0.6).
27. Blockade of proliferation and TNF- α production occurring during the mixed lymphocyte reaction by IFN- γ specific natural antibodies contained in intravenous immunoglobulins (IVIg). M. Toungouz, C. Denys, E. Dupont. **Transplantation**, 62, 1996: 1292-1296 (FI: 3.5)
28. Inhibition of IFN- γ production by intravenous immunoglobulins during mixed lymphocyte reaction (MLR): consequences for proliferation and TNF- α production.
29. M. Toungouz, C. Denys, E. Dupont ; **Transpl Proc**, 29, 1997:1089 (FI: 0.6).
30. Optimal control of IFN- γ and TNF- α by IL-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. **Transpl Proc**, 29, 1997:1422 (FI: 0.6).
31. Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins (IVIg) due to higher amounts of IFN- γ specific neutralizing antibodies. C. Denys, M. Toungouz and E. Dupont. **Vox Sanguinis**, 72, 1997:247-250. N.B. C. Denys et M. Toungouz ont contribué de manière équivalente à ce travail (FI 1.4).
32. Comprehensive HLA matching. E. Dupont, M. Toungouz, M. Andrien, P. Vereerstraeten. **Nephrology Dialysis and Transplantation**, 12, 1997 :2048-2050 (FI 1.8).

33. Heterogeneous response of B-lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukemia : correlation with the expression of TGF- β receptors. L. Lagneaux, A. Delforge, D. Bron, M. Bernier, M. Massy, P. Stryckmans. **British Journal of Haematology** 97;612-620,1997. (FI: 3.209)
34. Chronic lymphocytic leukemic B-cells but not normal B-cells are rescued from apoptosis by contact with normal bone marrow stromal cells. L. Lagneaux, A. Delforge, D. Bron, C. De Bruyn, P. Stryckmans. **Blood** 91(7):2387-2396,1998. (FI: 9.7 45)
35. TGF- β activity and expression of its receptors in B-cell chronic lymphocytic leukemia. L. Lagneaux, A. Delforge, M. Bernier, P. Stryckmans, D. Bron. **Leukemia & Lymphoma** 31: 99-106, 1998. (FI: 1.134)
36. Clinical remission and immune reconstitution after T cell depleted stem cell transplantation for rheumatoid arthritis. P. Durez, M. Toungouz, L. Schandene, M. Lambermont, M. Goldman. **The Lancet**, 352, 1998 : 881-882 (FI 18.3).
37. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells.L. Lagneaux, A. Delforge, C. De Bruyn, M. Bernier and D. Bron **Leukemia and lymphoma** 35(5.6): 445-453, 1999. (FI: 1.134)
38. CD47 ligation induces caspase-independant cell death in chronic lymphocytic leukaemia. V. Matéo, L. Lagneaux, D. Bron, G. Biron, M. Armant, G. Delespesse and M. Sarfati ; **Nature Medicine** 5(11):1277-1284, 1999. (FI: 1.134)
39. Regulation by P₂ agonists of the intracellular calcium concentration in epithelial cells freshly isolated from rat trachea. Marino, Y. Rodrig, M. Metioui, L. Lagneaux, E. Alzola, M. Fernandez, D. Fogarly, C. Matute, A. Moran and J.P. Dehaye. **Biochem Biophys Acta** 1439(3): 395-405, 1999. (FI: 2.411)
40. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines Interleukins-6 and -11. Sotiriou, M. Lacroix, L. Lagneaux, B. Berchem and JJ. Body. **Anticancer research** 19: 2997-3006, 1999. (FI: 1.100)
41. Cell therapy: basis for new therapeutic strategies. M. Toungouz, M. Lambermont, T. Velu. **Drug News and Perspectives**, 12, 1999: 12-20 (FI: 0.5).
42. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients. M. Toungouz, C. Quinet, E. Thille, S. Fourez, O. Pradier, J.P. Delville, T. Velu and M. Lambermont. **Cytotherapy**, 1, 1999: 447-453 (FI 0.8)
43. Bisphosphonates induce breast cancer cell death in vitro. O. Fromigue, L. Lagneaux and JJ. Body. **Journal of Bone Mineral Research** 15(11): 2211-2221, 2000. (FI: 5.793)

44. Immunotherapy using dendritic cells. T. Velu, M. Toungouz, L. Faid, M. Libin, F. Lehmann, M. Laporte, P. Vereecken, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman. **European Cytokine Network** 11: 306-308, 2000 (**FI: 1.8**).
45. Characterization of CD34⁺ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation. De Bruyn, A. Delforge, L. Lagneaux, D. Bron. **Bone Marrow transplantation** 25(4): 377-383, 2000. (**FI: 2.184**)
46. Transplantation tolerance and mixed chimerism : towards clinical applications. V. Donckier, M. Toungouz, M. Goldman. **Transpl. Int.** 14 :1-5, 2001 (**FI : 1.6**)
47. Hematopoietic stem cells : therapeutic applications in autoimmune diseases and in solid organ transplantation. M. Toungouz and M. Goldman. **Adv. Nephrol. Necker Hosp.**, 31:257-272, 2001.
48. Transient expansion of peptide-specific lymphocytes producing IFN- γ after vaccination with MAGE-A1/A3 positive tumors. M. Toungouz, M. Libin, F. Bulté, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman, T. Velu; **J. Leuk. Biol.**, 69 : 937-943, 2001 (**FI : 4.3**).
49. Anti-tumor immunotherapy based on dendritic cells. M. Toungouz, M. Lambermont, T. Velu, C. Buelens, N. Vanderheyde, E. Bartholomé, F. Willems, D. Gangji, M. Goldman. **J. Soc. Biol.**, 195 :19-23, 2001.
50. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. L. Lagneaux, A. Delforge, S. Carlier, M. Massy, M. Bernier and D. Bron. **British Journal of Haematology** 112(2): 344-352, 2001. (**FI: 3.209**)
51. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of bcl-2/bax ratio. L. Lagneaux, A. Delforge, M. Dejeneffe, M. Massy, M. Bernier and D. Bron. **Leukemia and Lymphoma** 43(5): 1087-1095, 2002. (**FI: 1.134**)
52. 2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. R. Snoeck, G. Andrei, B. Bodaghi, L. Lagneaux, D. Daelemans, E. de Clercq, J. Neyts, D. Schols, L. Naesens, S. Michelson, D. Bron, MJ Otto, A. Bousseau, C. Nemecek and C. Roy. **Antiviral Research** 55: 412-424, 2002. (**FI: 2.911**)
53. Ultrasonic low energy treatment: a novel approach to induce apoptosis in human leukemic cells. L. Lagneaux, E. Cordemans de Meulenaer, A. Delforge, M. Dejeneffe, M. Massy, C. Moerman, B. Hannecart, Y. Canivet, MF. Lepeltier and D. Bron. **Experimental Hematology** 30(11): 1293-1301, 2002. (**FI: 3.458**)

54. Chronic Lymphocytic Leukemia (CLL): New insight on the pathogenesis of CLL cell survival. L. Lagneaux, A. Delforge, M. Dejeneffe, M. Massy, M. Bernier and D. Bron. **Proceedings on the 7th Annual Meeting of the European Haematology Association-EHA** 193-198, 2002.
55. Hematopoietic stem cells: source, indications and perspectives. Bron, C. De Bruyn, L. Lagneaux, T. Tondreau and A. Delforge. **Bulletin et Mémoires de l'Académie Royale de Médecine de Belgique** 157 :135-145, 2002.
56. ¹¹¹In and ^{99m}Tc-HMPAO labelling of antigen loaded dendritic cells: in vivo imaging and influence on motility and actin content. Blocklet, M. Toungouz, R. Kiss, M. Lambermont, T. Velu, M. Goldman, S. Goldman. **Eur J Nucl Med**, 30:440-447, 2003. **(FI: 3.3)**
57. Tolerance induction in clinical transplantation: the pending questions. M. Toungouz, V. Donckier, M. Goldman. **Transplantation**, 75 :58-60, 2003 **(FI: 3.5)**
58. Infusion of donor CD34+ bone marrow cells in cadaver kidney transplantation : clinical data. L. De Pauw, M. Toungouz and M. Goldman. **Transplantation**, 75 :46-49, 2003 **(FI 3.5)**
59. Cytostatic and apoptotic effects of biphosphonates on prostate cancer cells JC. Dumon, F. Journé, N. Kheddoumi, L. Lagneaux and JJ. Body. **European Urology** 45(4):521-528, 2004. **(FI: 1.807)**
60. Isolation of bone marrow mesenchymal stem cells by plastic adhesion or negative depletion, proliferation kinetics and differentiation potential T. Tondreau, L. Lagneaux, M. Dejeneffe, A. Delforge, M. Massy, C. Mortier and D. Bron. **Cytotherapy** 6: 372-379, 2004. **(FI: 0.832)**
61. Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management. **Blood Cells Mol Dis** 33(3): 256-260. **(FI: 1.772)**
62. Bone-derived mesenchymal stem cells already express specific neural proteins before any differentiation. T. Tondreau, L. Lagneaux, M. Dejeneffe, A. Delforge, M. Massy, C. Mortier and D. Bron. **Differentiation** 72(7): 319-326, 2004. **(FI: 3.858)**
63. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells : a pilot study. V. Gangji, JP Hauzeur, C. Matos, V. De Maertelaer, M. Toungouz, M. Lambermont. **J Bone Joint Surg Am**, 86:1153-1160, 2004 **(FI 1.9)**
64. Donor stem cell infusion after non myeloablative conditioning for tolerance induction to HLA mismatched adult living-related liver graft. V. Donckier, R. Troisi, M. Toungouz, I. Colle, H. Van Vlierberghe, C. Jacky, P. Martiat, P. Stordeur, L. Zhou, N. Boon, M. Lambermont, L. Schandené, JL Van Laethem, L. Noens, M. Gelin, B. de Hemptinne, M. Goldman. **Transplant Immunol.**, 13:139-146, 2004 **(FI 1.7)**

65. Mesenchymal Stem Cells derived from CD133 positive cells in Mobilized Peripheral Blood and Cord Blood: proliferation, Oct4 expression and plasticity. T. Tondreau, N. Meuleman, A. Delforge, M. Dejeneffe, R. Leroy, M. Massy, C. Mortier, D. Bron, and L. Lagneaux. **Stem cells** 3:93-102, 2005(**FI: 5.802**)
66. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Achachi A, Florins A, Gillet N, Debacq C, Urbain P, Foutsop GM, Vandermeers F, Jasik A, Reichert M, Kerkhofs P, Lagneaux L, Burny A, Kettman R, Willems L. **Proc Natl Acad Sci USA** 102(29) :10309-10314, 2005.(**FI: 10.231**)
67. Interaction between estrogen receptor alpha, ionizing radiation and (anti)-estrogens in breast cancer cells. Toillon R, Magne N, Laios I, Lacroix M, Duvillier H, Lagneaux L, Devriendt D, Can Houtte P, Leclercq G **Breast Cancer Res Treat** 93(3) :207-215, 2005. (**FI :3.132**)
68. Immune characterization of clinical grade dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. M. Trakatelli, M. Toungouz, Van der Bruggen O, Lambermont M, Heenen M, Velu T, Bruyns C. **Cancer Gene Therapy**, 12:552-559, 2005 (**FI 3.7**).
69. A rapid test to monitor alloreactive response in whole blood using real-time PCR. L. Zhou, M. Toungouz, M. Andrien, E. Dupont, M. Goldman, P. Stordeur. **Transplantation**, 80:410-413, 2005. (**FI 3.6**)
70. IL-6 produced by type I IFN DC controls IFN-g production by blocking the suppressive effect of regulatory T cells. O. Detournay, N. Mazouz, M. Goldman and M. Toungouz. **Human Immunol**, 66:460-468, 2005 (**FI 2.6**)
71. Immunostimulatory properties of human dendritic cells generated using IFN- β associated with IL-3 or GM-CSF. N. Mazouz, O. Detournay, C. Buelens, J. Renneson, M. Trakatelli, M. Lambermont, A. Marchant, M. Goldman, M. Toungouz. **Cancer Immunol Immunother**, 54:1010-1017, 2005 (**FI 3.1**)
72. Stem cell therapy for the treatment of osteonecrosis. V. Gangji, M. Toungouz, J-P. Hauzeur. **Expert Opin Biol Ther**, 5:437-442, 2005 (**FI 2.8**)
73. Human marrow mesenchymal stem cell culture : serum-free medium allows better expansion than classical alpha-MEM medium. Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, Bron D, Lagneaux L. **Eur J Haematol** 76(4):309-316, 2006. (**FI:1.172**)
74. Intrathecal donor lymphocyte infusion for the treatment of suspected refractory lymphomatous meningitides: a case report. Meuleman N, Ahmad I, Duvillier H, Lemort M, Bennani J, Martiat P, Lagneaux L, D Bron. **Eur J Haematol** 77:523-526, 2006. (**FI:1.172**)

75. Bortezomib (PS-341, Velcade™) increases the efficacy of Trastuzumab (Herceptin®) in HER-2 positive breast cancer cells in a synergistic manner. Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C. **Mol Cancer Ther**, 5(12):3042-51, 2006. (FI:5.171)
76. A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. M. Trakatelli, M. Toungouz, D. Blocklet, Y. Dadoo, L. Gordower, M. Laporte, P. Vereecken, F. Sales, L. Mortier, N. Mazouz, M. Lambermont, S. Goldman, P. Coulie, M. Goldman, T. Velu. **Cancer Immunol Immunother**, 55:469-474, 2006 (FI 3.1)
77. Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. D. Blocklet, M. Toungouz, G. Berkenboom, M. Lambermont, P. Unger, N. Preumont, E. Stoupel, D. Egrise, J.P. Degaute, M. Goldman, S. Goldman. **Stem Cells**, 24:333-336, 2006 (FI 5.8)
78. Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives. M. Toungouz Névéssignsky, A. Ferster, **Nephrology Dialysis and Transplantation**, 21:1154-1157, 2006 (FI 2.6)
79. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Donckier V, Troisi R, Le Moine A, Toungouz M, Ricciardi S, Colle I, Van Vlierberghe H, Craciun L, Libin M, Praet M, Noens L, Stordeur, Andrien M, Lambermont M, Gelin M, Bourgeois N, Adler M, de Hemptinne B, Goldman M. **Liver Transplantation**, 12 : 1523-1528, 2006 (FI 4)
80. Valproic Acid potentiates TRAIL response and induces apoptosis in Chronic Lymphocytic Leukemia cells through activation of the death receptor pathway.
81. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specific hyporesponsiveness. L. Craciun, P. Stordeur, R. Troisi, A. Le Moine, M. Toungouz, I. Colle, H. Van Vlierberghe, P. Loi, V. Lucidi, B. de Hemptinne, M. Goldman, V. Donckier. **Transpl. Proc.**, 39:2665-7; 2007 (FI: 2.6)
82. Lagneaux L, Gillet N, Delforge A, Dejeneffe M, Stamatopoulos B, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D. **Experimental Hematology**, 35(10):1527-37, 2007. (FI: 4.019)
83. Zap-70 mRNA expression quantified in B cell by real time PCR is a powerful prognostic factor in Chronic Lymphocytic Leukemia. Stamatopoulos Basile, Meuleman Nathalie, Haibe-Kains Benjamin, Duvillier Hughes, Massy Martine, Martiat Philippe, Bron Dominique, Lagneaux Laurence. **Clinical Chemistry**, 53(10):1757-66, 2007. (FI : 7.7)

84. Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (HSCT) with Mesenchymal Stromal Cell (MSC) infusion for the Treatment of Metachromatic Leukodystrophy (MLD): a case report. N. Meuleman, G. Vanhaelen, T. Tondreau, P.Lewalle, J.Kwan, J.Bennani, P.Martiat, L.Lagneaux, D.Bron. **Haematologica**, 93(1):e11-13, 2008. (FI: 5.032)
85. Gene expression pattern of neuronal cells derived from human bone marrow mesenchymal stromal cells. T Tondreau, M Dejeneffe, N Meuleman, B Stamatopoulos, A Delforge, P Martiat, D Bron, L Lagneaux. **BMC Genomics**, 9:166, 2008. (FI : 4.18)
86. Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (HSCT) with Mesenchymal Stromal Cell (MSC) infusion for the Treatment of Metachromatic Leukodystrophy (MLD): a case report. N. Meuleman, G. Vanhaelen, T. Tondreau, P.Lewalle, J.Kwan, J.Bennani, P.Martiat, L.Lagneaux, D.Bron. **Haematologica**, 93(1):e48, 2008. (FI: 5.032)
87. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukaemia patients. N. Meuleman, B Stamatopoulos, M Dejeneffe, H El Housni, L Lagneaux, D Bron. **Leukemia**, 22(10); 1882-1890, 2008.(FI: 6.924)
88. Reduction of B cell turnover in chronic lymphocytic leukaemia. Defoiche J, Debacq C, Asquith B, Zhang Y, Burny A, Bron D, Lagneaux L, Macallan D, Willems L. **Br J Haematol**, 143(2), 240-247, 2008. (FI:4.49)
89. Valproate synergizes with nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells Bouzar A, Boxus M, Defoiche J, Berchem G, Macallan D, Petengel R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L. **Br J Haematol**, 144(1), 41-52, 2009. (FI:4.49)
90. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood : the importance of low cell ratio and role of interleukin -6. Najar M, Rouas R, Raicevic G, Id Boufker H, Lewalle P, Meuleman N, Bron D, Toungouz M, Martiat P, Lagneaux L. **Cytotherapy**, 11(5), 570-583(FI:3.55)
91. Gene expression profiling based on ZAP70 mRNA expression reveals differences in microenvironment interaction between poor and good prognostic patients. B Stamatopoulos, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, De Bruyn C, Hanosset D, Bron D, Martiat P, Lagneaux L. **Haematologica**, 94(6), 790-799, 2009 (FI :5.5)
92. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines : the role for their migration in injury tissues. Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, Martiat P, Bron D, Lagneaux L. **Cytotherapy**, 11(5), 559-569, 2009 (FI :3.55)

93. MicroRNA-29c and microRNA-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. B Stamatopoulos, N Meuleman, B Haibe-Kains, P Saussoy, E Van Den Neste, L Michaux, P Heimann, P Martiat, D Bron, L Lagneaux. **Blood**, 113(21), 5237-5245, 2009 (FI:10.896)
94. Human cystic fibrosis embryonic stem cell lines derived on placental mesenchymal stromal cells. Deleu S, Gonzalez-Merino E, Gaspard N, Nguyen TM, Vanderhaeghen P, Lagneaux L, Toungouz M, Englert Y, Devreker F. **Reprod Biomed Online**, 18(5), 704-716, 2009 (FI:2.84)
95. Infusion of Mesenchymal Stromal Cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Meuleman N, Tondreau T, Ahmad I, Kwan J, Crockaert F, Delforge A, Dorval C, Martiat P, Lewalle P, Lagneaux L, Bron D. **Stem Cells Dev**, 18(9), 1247-1252, 2009 (FI:3.224)
96. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejefeffe M, Martiat P, Bron D, Lagneaux L. **Cytotherapy**, 11(5), 559-569, 2009 (FI :3.55)
97. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and the role of interleukin-6. Najar M, Rouas R, Raicevic G, Boufker H, Lewalle P, Meuleman N, Bron D, Toungouz M, Martiat P, Lagneaux L. **Cytotherapy**, 11(5), 570-583, 2009 (FI :3.55).
98. Measurement of ribosomal RNA turnover in vivo by use of deuterium-labeled glucose. Defoiche J, Zhang Y, Lagneaux L, Pettengel R, Hegedus A, Willems L, Macallan DC. **Clin Chem**, 55(10), 1824-1833, 2009 (FI:4.8).
99. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L. **Leukemia**, 23(12), 2281-2289, 2009 (FI :6.924).
100. Myocardial homing and coronary endothelial function after autologous blood CD34+ progenitor cells intracoronary injection in the chronic phase of myocardial infarction. C. Dedobbeleer, Didier Blocklet, M. Toungouz , M., P. Unger, J.P. Degaute, S. Goldman, G. Berkenboom **Journal of Cardiovascular Pharmacology**, 53:480-485, 2009

101. Human cystic fibrosis embryonic stem cell lines derived on placental mesenchymal stromal cells S. Deleu, M.U. Nguyen Thi, E. Gonzalez-Merino, N. Gaspard, P. Vanderhaegen, M. Toungouz, Y. Englert, F. Devreker **Reproductive Biomedicine Online**, 18:704-716, 2009
102. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Raicevic G, Rouas R, Najar M, Stordeur P, Id Boufker H, Bron D, Martiat P, Goldman M, Nevessignsky MT, Lagneaux L. **Hum Immunol**, 2010 Jan 6 (**FI:2.9**).
103. The histone deacetylase inhibitor suberoyanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. **Haematologica**, 2010 Feb 9 (**FI :5.5**).
104. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Raicevic G, Rouas R, Najar M, Stordeur P, Boukker H, Bron D, Martiat P, Goldman M, Nevessignsky M, Lagneaux L. **Hum Immunol** 71(3):235-244, 2010 (**FI :2.9**).
105. The histone deacetylase inhibitor suberoyanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. **Haematologica**, 95(7), 1136-1143, 2010 (**FI :5.5**).
106. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journé F. **BMC Cancer** 10; 298, 2010 (**FI :2.74**).
107. Modulated expression of adhesion molecules and galectin-1: Role during mesenchymal stromal cell immunoregulatory functions. Najar M, Raicevic G, Id Boufker H, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. **Exp Hematol** 2010, 264(2);171-179 (**FI: 3.106**).
108. Adipose tissue and Wharton's Jelly derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Najar M, Raicevic G, Id Boufker H, Fayyad Kazan H, Debruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. **Tissue Eng Part A** 2010, 16(11); 3537-3546 (**FI: 4.582**).
109. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Najar M, Raicevic G, Boufker HI, Kazan HF, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. **Cell Immunol** 2010; 264:171-9 (**FI: 2.698**).

110. In vivo ribosomal RNA turnover is down-regulated in leukaemic cells in chronic lymphocytic leukaemia. Defoiche J, Zhang Y, Lagneaux L, Willems L, Macallan DC. **Br J Haematol** 151(12):192-195, 2010 (FI: 4.597).
111. A rapid, simple and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, Delforge A, Bron D, Lagneaux L. **Stem Cells Dev** 20(3):547-557, 2010 (FI: 4.146).
112. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Anthoine G, Mineur P, Bron D, Lagneaux L. **Plos One** 5(9) e12780, 2010 (FI: 4.351).
113. MICA antibodies: sensitizing events and impact on renal graft outcomes. Lemy, M. Andrien, KM Wissing, K. Ryahi, A. Vandersarren, J. Racapé, C. Heylen, L. Ghysdal, N. Broeders, P. Vereerstraeten, M. Toungouz and D. Abramowicz. **Transplantation**, 90:168-174, 2010 (FI 3.5)
114. Computer-aided HLA association studies: a case study for psoriasis and severe alopecia areata. D. Catanzaro, M. Andrien, M. Labbé, M. Toungouz Nevessignsky. **Human Immunology**, 71:783-8, 2010, (FI 2.9)
115. Bortezomib: a new player in pre- and post-transplant desensitization? Lemy, M. Toungouz, D. Abramowicz. **Nephrology Dialysis and Transplantation** 25:3480-9, 2010, (FI 2.6)
116. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Raicevic G, Najar M, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. **Cell Immunol** 270(2):207-216, 2011 (FI:2.575).
117. Role of farnesoid X receptor (FXR) in the process of differentiation of mesenchymal stromal cells into osteoblasts. Id Boufker H, Lagneaux L, Fayyad-Kazan H, Badran B, Najar M, Wiedig M, Ghanem G, Laurent G, Body JJ, Journé F. **Bone** 49(6) :1219-1231 2011 (FI :4.601).
118. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell -based microenvironment: preclinical evidence for its association with chronic lymphocytic leukemia treatments. Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N, Cymbalista F, Bron D, Lagneaux L. **Haematologica** 2011, Nov 4 (FI:6.532).
119. Inflammation and TLR ligation differentially affect the osteogenic potential of human mesenchymal stromal cells (MSC) depending on their tissue origin. Raicevic

G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. **Tissue Engineering** 2012 (in press) (FI :4.636).

120. Assessment of the intrinsic pluripotency of mesoderm-derived stem cells from different niches. Joery De Kock, M Najar, J Bolleyn, Al Battah F, Raicevic G, Govaere O, Branson S, Meganathan K, Gaspar JA, Roskams T, Sachinidis A, Lagneaux L, Vanhaecke T and V Rogiers. **Altex** 2012 (in press) (FI:4.3).
121. Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. Joery De Kock, M Najar, J Bolleyn, Al Battah F, Rodriguez RM, Raicevic G, Govaere O, Branson S, Meganathan K, Gaspar JA, Roskams T, Sachinidis A, Lagneaux L, Vanhaecke T and V Rogiers. **Stem Cells and Development** 2012 (submitted) (FI:4.8).
122. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. C Desmedt, S Majjaj, N Kheddoumi, SK. Singhal, B Haibe-Kains, F El Ouriaghli, C Chaboteaux, S Michiels, F Lallemand, F Journe, H Duvillier, S Loi, J Quackenbush, S Dekoninck, C Blanpain, L Lagneaux, N Houhou, M Delorenzi, D Larsimont, M Piccart⁹, C Sotiriou **Clin Cancer Res** 2012 (in press) (FI:7.338).